CEO's Guide to Low-Cost, Non-Dilutive Revenue Interest Financing (RIF) Capital
By Lionel Leventhal, Fedora Baloiu
With precipitous decreases of as much as 50% or more in the equity market capitalizations of many pharma, biotech, medical device, and diagnostics/tools companies over the past year, Royalty and Revenue Interest Financing (a.k.a. “RIF” and “synthetic royalty financing”) has become a valuable tool for CFOs of both public and private commercial-stage companies to raise significant amounts of non-dilutive capital, often at a capped rate of return of as low as 10–15%.
Download it here